Table 2 provides a comprehensive overview of the key randomized clinical trials evaluating SGLT2 inhibitors in various heart failure populations, summarizing essential trial characteristics, inclusion criteria, primary endpoints, and major outcome findings. Here, SLC5A2 is linked to heart failure.